Texas 2025 - 89th Regular

Texas House Bill HB4638 Latest Draft

Bill / Comm Sub Version Filed 04/30/2025

                            89R25426 MPF-D
 By: Bonnen H.B. No. 4638
 Substitute the following for H.B. No. 4638:
 By:  VanDeaver C.S.H.B. No. 4638




 A BILL TO BE ENTITLED
 AN ACT
 relating to the Texas Pharmaceutical Initiative.
 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
 SECTION 1.  Section 2177.003(a), Government Code, is amended
 to read as follows:
 (a)  The initiative is governed by a board composed of five
 [three] members appointed by the governor.
 SECTION 2.  Chapter 2177, Government Code, is amended by
 adding Section 2177.0035 to read as follows:
 Sec. 2177.0035.  TERMS; VACANCIES.  (a)  Board members serve
 staggered six-year terms, with one-third or as near as possible to
 one-third of the members' terms expiring February 1 of each
 odd-numbered year.
 (b)  A vacancy on the board shall be filled for the unexpired
 term in the same manner as the original appointment.
 SECTION 3.  Section 2177.006, Government Code, is amended to
 read as follows:
 Sec. 2177.006.  BUSINESS PLAN. Not later than June 1 of each
 even-numbered year [October 1, 2024], the board shall prepare
 [develop] and submit to the governor, the legislature, and the
 Legislative Budget Board a business plan on:
 (1)  implementing the initiative, including the
 initiative's organizational structure and related programs;
 (2)  establishing procedures and policies for the
 administration of the initiative, including documenting the
 process and resources required for the provision to individuals
 described by Section 2177.002 of the following services:
 (A)  establishing or contracting for statewide
 pharmacy benefit manager services;
 (B)  establishing policies and conditions to
 operate or contract for the operation of a distribution network,
 central service center, and associated network of satellite
 distribution facilities to distribute prescription drugs and
 related medical supplies; and
 (C)  providing advanced pharmaceutical
 preparation and related services, including:
 (i)  manufacturing generic drugs and generic
 biological products;
 (ii)  providing gene therapies and precision
 medicine; and
 (iii)  providing advanced laboratories for
 quality control, preparation, and compounding of drugs in support
 of innovative therapeutics and drug research;
 (3)  establishing procedures to document compliance by
 board members and personnel with applicable laws governing
 conflicts of interest;
 (4)  establishing the conditions for state agencies
 that facilitate health plans to participate in the initiative;
 (5)  identifying potential cost savings from
 implementation of the initiative;
 (6)  identifying the funding and resources needed to
 implement this chapter;
 (7)  providing recommendations on best practices and
 cost savings related to the provision of pharmacy benefits using
 program utilization; and
 (8) [(7)]  providing other board recommendations, with
 supporting documentation, on continuation of the initiative.
 SECTION 4.  Section 2177.010, Government Code, is amended to
 read as follows:
 Sec. 2177.010.  EXPIRATION OF CHAPTER. This chapter expires
 September 1, 2031 [2025].
 SECTION 5.  (a)  As soon as practicable after the effective
 date of this Act, the governor shall appoint the governing board
 members for the Texas Pharmaceutical Initiative as required by
 Section 2177.003, Government Code, as amended by this Act.
 (b)  Notwithstanding Section 2177.0035, Government Code, as
 added by this Act, in making the appointments of the governing board
 members for the Texas Pharmaceutical Initiative under Subsection
 (a) of this section, the governor shall designate:
 (1)  two members to serve terms expiring February 1,
 2027;
 (2)  two members to serve terms expiring February 1,
 2029; and
 (3)  one member to serve a term expiring February 1,
 2031.
 SECTION 6.  This Act takes effect September 1, 2025.